Skip to main content

In the pursuit to cure* chronic hepatitis C virus (HCV) genotype 1 infection…Consider OLYSIO® for your patients with 24 weeks’ treatment duration

100% (10/10) of patients with cirrhosis achieved cure* in the 24-week group

Overall cure* rates in the 24-week group in OLYSIO<sup>®</sup> clinical trial

IFN- and RBV-free treatment option = OLYSIO® + sofosbuvir (SOF)

  • 24 weeks of treatment duration for patients with cirrhosis

Use with RBV

  • Results from treatment arms containing RBV in addition to OLYSIO® and sofosbuvir in the COSMOS trial are not shown because efficacy was similar with or without RBV, and thus addition of RBV to OLYSIO® and sofosbuvir is not recommended.

IFN=interferon; P/R=peginterferon/ribavirin; RBV=ribavirin.

*Virologic cure (SVR12) was defined as sustained virologic response 12 weeks after the planned end of treatment (EOT).

Null responders to prior P/R therapy.

Viral relapse rates are calculated with a denominator of subjects with HCV RNA not detected at EOT and with at least 1 follow‐up HCV RNA assessment.

COSMOS (IFN-free) study design and baseline demographics

COSMOS study design

IFN- and RBV-free treatment option = OLYSIO® + SOF

COSMOS: open‑label, randomized Phase 2 trial to investigate the efficacy and safety of 12 or 24 weeks of OLYSIO® in combination with SOF without or with RBV in HCV genotype 1‑infected prior null responders with METAVIR fibrosis score F0‑F2, or treatment‑naïve subjects and prior null responders (to P/R therapy) with METAVIR fibrosis score F3‑F4 and compensated liver disease.

  • OLYSIO® 150 mg once daily + SOF 400 mg once daily
  • Primary endpoint: SVR12: sustained virologic response 12 weeks after planned end of treatment [EOT]

IFN=interferon; P/R=peginterferon/ribavirin; RBV=ribavirin; SOF=sofosbuvir.

*This case is representative of a patient in the COSMOS clinical trial. The image is not of an actual patient studied in COSMOS.

Baseline demographic and disease characteristics in OLYSIO® + SOF without RBV arms

COSMOS Baseline Demographics